Flexion Therapeutics (FLXN) Receives a Buy from RBC Capital
In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Flexion Therapeutics (FLXN), with a price target of $20.00. The company’s shares closed last Monday at $7.58, close to its 52-week low of $5.01.
According to TipRanks.com, Stanicky is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -21.5% and a 18.4% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.
Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.88, which is a 300.0% upside from current levels. In a report issued on March 13, Needham also maintained a Buy rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
Based on Flexion Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $23.65 million and GAAP net loss of $33.52 million. In comparison, last year the company earned revenue of $9.54 million and had a GAAP net loss of $40.58 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.